Sarcoidosis of the nervous system

Practical Neurology

Volumn 7, Issue 4, 2007, Pages 234-244

  Joseph, F G ^a   Scolding, N J ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; AZATHIOPRINE; CHLORAMBUCIL; CHLOROQUINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUORODEOXYGLUCOSE F 18; GALLIUM CITRATE GA 67; HYDROXYCHLOROQUINE; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENTOXIFYLLINE; PHENYTOIN; PREDNISOLONE; STEROID; THALIDOMIDE;

BLADDER CANCER; BLOOD ANALYSIS; BRAIN SCINTISCANNING; BRAIN STEM INJURY; CENTRAL NERVOUS SYSTEM DISEASE; CEREBELLUM INJURY; CEREBROSPINAL FLUID; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CRANIAL NEUROPATHY; DEPRESSION; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FACIAL NERVE PARALYSIS; HUMAN; KVEIM TEST; LIVER INJURY; LOW DRUG DOSE; LYMPHADENOPATHY; MENINGITIS; MENTAL DISEASE; MOTOR DYSFUNCTION; MUSCLE DISEASE; NERVE BIOPSY; NEUROIMAGING; NEUROLOGIC DISEASE; NEUROPHYSIOLOGY; NEUROSURGERY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; POSITRON EMISSION TOMOGRAPHY; REVIEW; SARCOIDOSIS; SEIZURE; SPINAL CORD DISEASE; THORAX RADIOGRAPHY; UNSPECIFIED SIDE EFFECT;

AUTOIMMUNE DISEASES OF THE NERVOUS SYSTEM; BRAIN; CRANIAL NERVE DISEASES; GRANULOMA; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MENINGITIS, ASEPTIC; OPTIC NERVE DISEASES; SARCOIDOSIS; SKULL BASE;

EID: 34547564391     PISSN: 14747758     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.2007.124263     Document Type: Review

References (89)

1. Hosoda Y, Sasagawa S, Yasuda N. Epidemiology of sarcoidosis: new frontiers to explore. Curr Opin Pulm Med 2002;8:424-8.
2. Baughman RP, Teirstein AS, Judson MA, et al. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med 2001;164:1885-9.
3. Rybicki BA, Iannuzzi MC, Frederick MM, et al. Familial aggregation of sarcoidosis. A case-control etiologic study of sarcoidosis (ACCESS). Am J Respir Crit Care Med 2001;164:2085-91.
4. Martinetti M, Tinelli C, Kolek V, et al. "The sarcoidosis map": a joint survey of clinical and immunogenetic findings in two European countries. Am J Respir Crit Care Med 1995; 152:557-64.
5. Moller DR, Chen ES. What causes sarcoidosis? Curr Opin Pulm Med 2002;8:429-34.
6. Stern BJ. Neurological complications of sarcoidosis. Curr Opin Neurol 2004;17:311-16.
7. Trevenzoli M, Cattelan AM, Marino F, et al. Sarcoidosis and HIV infection: a case report and a review of the literature. Postgrad Med J 2003;79:535-8.
8. Morris DG, Jasmer RM, Huang L, et al. Sarcoidosis following HIV infection: evidence for CD4+ lymphocyte dependence. Chest 2003; 124:929-35.
9. Heerfordt CF. Über eine "Febris uveo-parotidea subchronica" an der Glandula parotis und der Uvea des Auges lokalisiert und häufug mit Paresen cerebrospinaler Nerven kompliziert. Albrecht von Grafes Archiv für Ophthalmologie 1909;70:254-73.
10. Keynes M. The personality, deafness, and bad health of Ludwig van Beethoven. J Med Biogr 2002;10:46-57.
11. Sharma OP. Beethoven's illness: Whipple's disease rather than sarcoidosis? J R Soc Med 1994;87:283-5.
12. Drake ME Jr. Deafness, dysesthesia, depression, diarrhea, dropsy, and death: the case for sarcoidosis in Ludwig van Beethoven. Neurology 1994;44:562-5.
13. Palferman TG. Classical notes: Beethoven's medical history. Variations on a rheumatological theme. J R Soc Med 1990;83:640-5.
14. Oksanen V. Neurosarcoidosis: clinical presentations and course in 50 patients. Acta Neurol Scand 1986;73:283-90.
15. Stern BJ, Krumholz A, Johns C, et al. Sarcoidosis and its neurological manifestations. Arch Neurol 1985;42:909-17.
16. Chen RC, McLeod JG. Neurological complications of sarcoidosis. Clin Exp Neurol 1989;26:99-112.
17. James DG, Sharma OP. Neurosarcoidosis. Proc R Soc Med 1967; 60:1169-70.
18. Iwai K, Tachibana T, Takemura T, et al. Pathological studies on sarcoidosis autopsy. I. Epidemiological features of 320 cases in Japan. Acta Pathol Jpn 1993;43:372-6.
19. Zajicek JP, Scolding NJ, Foster O, et al. Central nervous system sarcoidosis-diagnosis and management. OJM 1999;92:103-17.
20. Nowak DA, Widenka DC. Neurosarcoidosis: a review of its intracranial manifestation. J Neurol 2001;248:363-72.
21. Kohler A, Chofflon M, Sztajzel R, et al. Cerebrospinal fluid in acute peripheral facial palsy. J Neurol 1999;246:165-9.
22. Sharma OP. Neurosarcoidosis: a personal perspective based on the study of 37 patients. Chest 1997;112:220-8.
23. Lower EE, Broderick JP, Brott TG, Baughman RP. Diagnosis and management of neurological sarcoidosis. Arch Intern Med 1997; 157:1864-8.
24. Sponsler JL, Werz MA, Maciunas R, et al. Neurosarcoidosis presenting with simple partial seizures and solitary enhancing mass: case reports and review of the literature. Epilepsy Behav 2005; 6:623-30.
25. Krumholz A, Stern BJ, Stern EG. Clinical implications of seizures in neurosarcoidosis. Arch Neurol 1991;48:842-4.
26. Delaney P. Neurologic manifestations in sarcoidosis: review of the literature, with a report of 23 cases. Ann Intern Med 1977; 87:336-45.
27. Borucki SJ, Nguyen BV, Ladoulis CT, et al. Cerebrospinal fluid immunoglobulin abnormalities in neurosarcoidosis. Arch Neurol 1989;46:270-3.
28. Veres L, Utz JP, Houser OW. Sarcoidosis presenting as a central nervous system mass lesion. Chest 1997;111:518-21.
29. Gizzi MS, Lidov M, Rosenbaum D. Neurosarcoidosis presenting as a tumour of the basal ganglia and brainstem: sequential MRI. Neurol Res 1993;15:93-6.
30. Miller DH, Kendall BE, Barter S, et al. Magnetic resonance imaging in central nervous system sarcoidosis. Neurology 1988; 38:378-83.
31. Rieger J, Hosten N. Spinal cord sarcoidosis. Neuroradiology 1994;36:627-8.
32. Sharma OP, Sharma AM. Sarcoidosis of the nervous system. A clinical approach. Arch Intern Med 1991;151:1317-21.
33. Bogousslavsky J, Hungerbuhler JP, Regli F, et al. Subacute myelopathy as the presenting manifestation of sarcoidosis. Acta Neurochir (Wien) 1982;65:193-7.
34. Caroscio JT, Yahr MD. Progressive myelopathy due to sarcoid. Clin Neurol Neurosurg 1980;82:217-22.
35. Bona JR, Fackler SM, Fendley MJ, et al. Neurosarcoidosis as a cause of refractory psychosis: a complicated case report. Am J Psychiatry 1998;155:1106-8.
36. O'Brien GM, Baughman RP, Broderick JP, et al. Paranoid psychosis due to neurosarcoidosis. Sorcoidosis 1994;11:34-6.
37. Sabaawi M, Gutierrez-Nunez J, Fragala MR. Neurosarcoidosis presenting as schizophreniform disorder. Int J Psychiatry Med 1992; 22:269-74.
38. Stoudemire A, Linfors E, Houpt JL Central nervous system sarcoidosis. Gen Hosp Psychiatry 1983;5:129-32.
39. Miller R, Sheron N, Semple S. Sarcoidosis presenting with an acute Guillain-Barre syndrome. Postgrad Med J 1989;65:765-7.
40. Otake S, Ishigaki T. Muscular sarcoidosis. Semin Musculoskelet Radiol 2001;5:167-70.
41. Fayad F, Liote F, Berenbaum F, et al. Muscle involvement in sarcoidosis: a retrospective and followup studies. J Rheumatol 2006;33:98-103.
42. Pickuth D, Heywang-Kobrunner SH. Neurosarcoidosis: evaluation with MRI. J Neuroradiol 2000;27:185-8.
43. Mana J. Magnetic resonance imaging and nuclear imaging in sarcoidosis. Curr Opin Pulm Med 2002;8:457-63.
44. Dubey N, Miletich RS, Wasay M, et al. Role of fluorodeoxyglucose positron emission tomography in the diagnosis of neurosarcoidosis. J Neurol Sci 2002;205:77-81.
45. Ng D, Jacobs M, Mantil J. Combined C-11 methionine and F-18 FDG PET imaging in a case of neurosarcoidosis. Clin Nucl Med 2006; 31:373-5.
46. Oksanen V, Fyhrquist F, Somer H, et al. Angiotensin converting enzyme in cerebrospinal fluid: a new assay. Neurology 1985; 35:1220-3.
47. Tahmoush AJ, Amir MS, Connor WW, et al. CSF-ACE activity in probable CNS neurosarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2002;19:191-7.
48. Dale J. determination of angiotensin-converting enzyme levels in cerebrospinal fluid is not a useful test for the diagnosis of neurosarcoidosis. Mayo Clin Proc 1999;74:535.
49. Oksanen V. New cerebrospinal fluid, neurophysiological and neuroradiological examinations in the diagnosis and follow-up of neurosarcoidosis. Sarcoidosis 1987;4:105-10.
50. Adachi N. Beta-2-microglobulin levels in the cerebrospinal fluid: their value as a disease marker. A review of the recent literature. Eur Neurol 1991;31:181-5.
51. Oksanen V, Gronhagen-Riska C, Tikanoja S, et al. Cerebrospinal fluid lysozyme and beta 2-microglobulin in neurosarcoidosis. J Neurol Sci 1986;73:79-87.
52. Li CY, Yam LT. Cytologic and immunocytochemical studies of cerebrospinal fluid in meningeal sarcoidosis. A case report. Acta Cytol 1992; 36:963-7.
53. Stern BJ, Griffin DE, Luke RA, et al. Neurosarcoidosis: cerebrospinal fluid lymphocyte subpopulations. Neurology 1987; 37:878-81.
54. Marangoni S, Argentiero V, Tavolato B. Neurosarcoidosis: Clinical description of 7 cases with a proposal for a new diagnostic strategy. J Neurol 2006;253:488-95.
55. Oksanen V, Salmi T. Visual and auditory evoked potentials in the early diagnosis and follow-up of neurosarcoidosis. Acta Neurol Scand 1986;74:38-42.
56. Verma NP, Desai SG, Simon MR, et al. Multimodality evoked potentials in sarcoidosis. J Lab Clin Med 1988;111:692-700.
57. Matsumoto R, Shintaku M, Suzuki S, et al. Cerebral perivenous calcification in neuropsychiatric lupus erythematosus: a case report. Neuroradiology 1998;40:583-6.
58. Hoitsma E, Marziniak M, Faber CG, et al. Small fibre neuropathy in sarcoidosis. Lancet 2002;359:2085-6.
59. Rothkrantz-Kos S, van Dieijen-Visser MP, Mulder PG, et al. Potential usefulness of inflammatory markers to monitor respiratory functional impairment in sarcoidosis. Clin Chem 2003; 49:1510-17.
60. Nuria A, Reis A, Bernardo J, et al. [Mediastinoscopy in the diagnose of sarcoidosis]. Rev Port Pneumol 2003;9(Suppl 5):36-7.
61. Segal EI, Tang RA, Lee AG, et al. Orbital apex lesion as the presenting manifestation of sarcoidosis. J Neuroophthalmol 2000; 20:156-8.
62. Makhija MC, Anayiotos CP. Gallium scan in intracerebral sarcoidosis. Clin Nucl Med 1981;6:324-7.
63. Hegab SM, al-Mutawa SA, Sheriff SM. Sarcoidosis presenting as multilobular limbal corneal nodules. J Pediatr Ophthalmol Strabismus 1998;35:323-6.
64. Braun M, Jonas JB. [Band-like corneal degeneration as the initial sign of sarcoidosis]. Klin Monatsbl Augenheilkd 1996;209:328-9.
65. Volcker HE, Naumann GO. [Sarcoidosis of the eye. Biomicroscopic and histopathologic findings]. Klin Monatsbl Augenheilkd 1985; 187:83-91.
66. Silverstein A, Siltzbach LE. Muscle involvement in sarcoidosis. Asymptomatic, myositis, and myopathy. Arch Neurol 1969; 21:235-41.
67. Scala RH, Werneck LC, Prevedello DM, et al. Symptomatic muscle involvement in neurosarcoidosis: a clinicopathological study of 5 cases. Arq Neuropsiquiatr 2001;59:347-52.
68. Agbogu BN, Stern BJ, Sewell C, et al. Therapeutic considerations in patients with refractory neurosarcoidosis. Arch Neurol 1995; 52:875-9.
69. Sharma OP. Effectiveness of chloroquine and hydroxychloroquine in treating selected patients with sarcoidosis with neurological involvement Arch Neurol 1998;55:1248-54.
70. Johns CJ, Michele TM. The clinical management of sarcoidosis. A 50-year experience at the Johns Hopkins Hospital. Medicine (Baltimore) 1999;78:65-111.
71. Dumas JL, Valeyre D, Chapelon-Abric C, et al. Central nervous system sarcoidosis: follow-up at MR imaging during steroid therapy. Radiology 2000;214:411-20.
72. Stern BJ, Schonfeld SA, Sewell C, et al. The treatment of neurosarcoidosis with cyclosporine. Arch Neurol 1992; 49:1065-72.
73. Kouba DJ, Mimouni D, Rencic A, et al. Mycophenolate mofetil may serve as a steroid-sparing agent for sarcoidosis. Br J Dermatol 2003;148:147-8.
74. Bullmann C, Faust M, Hoffmann A, et al. Five cases with central diabetes insipidus and hypogonadism as first presentation of neurosarcoidosis. Eur J Endocrinol 2000;142:365-72.
75. Ferriby D, de Seze J, Stojkovic T, et al. [Clinical manifestations and therapeutic approach in neurosarcoidosis]. Rev Neurol (Paris) 2000;156:965-75.
76. Roach DR, Bean AG, Demangel C, et al. TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. J Immunol 2002; 168:4620-7.
77. Zheng L, Teschler H, Guzman J, et al. Alveolar macrophage TNF-alpha release and BAL cell phenotypes in sarcoidosis. Am J Respir Crit Care Med 1995;152:1061-6.
78. Baughman RP, Strohofer SA, Buchsbaum J, et al. Release of tumor necrosis factor by alveolar macrophages of patients with sarcoidosis. J Lab Clin Med 1990;115:36-42.
79. Doty JD, Mazur JE, Judson MA. Treatment of sarcoidosis with infliximab. Chest 2005;127:1064-71.
80. Sollberger M, Fluri F, Baumann T, et al. Successful treatment of steroid-refractory neurosarcoidosis with infliximab. J Neurol 2004;251:760-1.
81. Carter JD, Valeriano J, Vasey FB, et al. Refractory neurosarcoidosis: a dramatic response to infliximab. Am J Med 2004;117:277-9.
82. Morcos Z. Refractory neurosarcoidosis responding to infliximab. Neurology 2003;60:1220-1; author reply 1220-1.
83. Pettersen JA, Zochodne DW, Bell RB, et al. Refractory neurosarcoidosis responding to infliximab. Neurology 2002; 59:1660-1.
84. Kang S, Suh JH. Radiation therapy for neurosarcoidosis: report of three cases from a single institution. Radiat Oncol Investig 1999; 7:309-12.
85. Manterola-Burgaleta A, Teijeira-Garcia M, Duenas-Polo MT. [Neurosarcoidosis. Apropos of a case and review of the literature]. Rev Neurol 2001;32:57-9.
86. Gelwan MJ, Kellen RI, Burde RM, et al. Sarcoidosis of the anterior visual pathway: successes and failures. J Neurol Neurosurg Psychiatry 1988;51:1473-80.
87. Foley KT, Howell JD, Junck L. Progression of hydrocephalus during corticosteroid therapy for neurosarcoidosis. Postgrad Med J 1989;65:481-4.
88. Hamada H, Hayashi N, Kurimoto M, et al. Isolated third and fourth ventricles associated with neurosarcoidosis successfully treated by neuroendoscopy - case report. Neurol Med Chir (Tokyo) 2004; 44:435-7.
89. Maniker AH, Cho ES, Schulder M. Neurosarcoid infiltration of the ventricular catheter causing shunt failure: a case report. Surg Neurol 1997;48:527-9.